Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.
about
Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomalleiProphylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosisMelioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposesVisualization of murine intranasal dosing efficiency using luminescent Francisella tularensis: effect of instillation volume and form of anesthesia.The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.Treatment and prophylaxis of melioidosisA gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei.Development of vaccines against burkholderia pseudomallei.Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice.Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunityBurkholderia vaccines: are we moving forward?Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.Monitoring Therapeutic Treatments against Burkholderia Infections Using Imaging TechniquesCpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits.Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.Burkholderia pseudomallei: Challenges for the Clinical Microbiology LaboratoryRapid DNA vaccination against Burkholderia pseudomallei flagellin by tattoo or intranasal application.
P2860
Q27305217-10BD3273-CB57-4567-ACDE-12D290C20220Q27305350-9ADB1ADD-CC0D-45B6-8094-FA0C31634A21Q27305733-68D6ABC9-0BBB-4755-AD5E-5FC1AB935700Q34181668-24B1C659-90BD-44D6-809A-2B85EE5650BDQ34275632-F40F3287-475C-4357-9A46-BFDEDA9FB7F2Q34538191-3CD734F4-1C84-4CDB-8DF4-DFC1FB4F4A05Q35088366-698F563D-DC3C-4A1B-A622-46EC3AEB863CQ35234118-CF626F0F-1C09-43BD-BFF9-EF60F40EF400Q35940681-E1AC9AA3-2B60-47FF-AD8B-6FBAA8D20C0FQ36163108-33EBFCAD-CC20-4759-A1C5-058883542D76Q36587103-EE2BF136-D6E4-4807-A8D7-556A8AB0067EQ36911486-5DAE7431-F160-490B-88E2-07BB3AAF5B75Q37384332-1A22A6BA-3E38-4C8C-A7AF-6F6F093CF5A3Q37521856-5E95FD7A-5FD8-48CF-8094-205E08B9A58CQ38890754-F7AFDB05-BF31-4710-AEDF-7C7B9C5ADACAQ38961000-E0D51C0C-F238-4CAC-A0EA-B90329CEC070Q40286028-DAE7B00D-8FA1-4A2B-A4A5-ADE03AF2D606
P2860
Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Combining vaccination and post ...... se model of human melioidosis.
@ast
Combining vaccination and post ...... se model of human melioidosis.
@en
type
label
Combining vaccination and post ...... se model of human melioidosis.
@ast
Combining vaccination and post ...... se model of human melioidosis.
@en
prefLabel
Combining vaccination and post ...... se model of human melioidosis.
@ast
Combining vaccination and post ...... se model of human melioidosis.
@en
P2093
P2860
P356
P1476
Combining vaccination and post ...... se model of human melioidosis.
@en
P2093
Anna Easton
Arthur M Krieg
Gregory J Bancroft
Natasha Patel
Roman A Lukaszewski
P2860
P304
P356
10.1093/INFDIS/JIR301
P407
P577
2011-08-01T00:00:00Z